Nigeria GMP Guideline DER-GDL-025-00: Scope, Key Clauses and Compliance Actions

1. Key takeaways

The operative Good Manufacturing Practice (GMP) basis for medical devices in Nigeria is the NAFDAC Good Manufacturing Practice (GMP) for Medical Devices, IVDs and Related Products Guidelines 2024. For any manufacturer supplying the Nigerian market, this document is the reference against which factory inspections and quality system reviews are actually conducted. Its essential parameters are as follows:

• Document number: DER-GDL-025-00;
• Effective date: 11 November 2024; review date: 10 November 2029;
• Responsible directorate: the DER Directorate (Drug Evaluation and Research);
• Positioning: the guideline converts a quality management system from a single ISO 13485 certificate into a set of clauses that can be verified one by one during an on-site inspection.

The practical significance of this last point deserves emphasis. Many exporters assume that an ISO 13485 certificate satisfies Nigerian quality system expectations. The 2024 guideline takes a different approach: it decomposes the quality system into specific, checkable requirements, so an inspector can point to a clause and ask the manufacturer to demonstrate conformity on the spot. The key chapters are:

• §11.3–§11.7: nonconforming product control, rework, and corrective and preventive action (CAPA);
• §12.0–§12.10: device labelling (including UDI, labelling SOPs, and labelling of sterile devices);
• §13.1: complaint handling; §13.2: product recall (including mock recalls).

Manufacturers preparing for a Nigerian GMP inspection should treat these three clusters as the core of their readiness programme, because they are the areas where documentation gaps are easiest for an inspector to detect.

2. Legal basis

Together, these three instruments form a closed loop: the guideline describes what a conforming quality system looks like, the registration guideline tells applicants when a GMP inspection will be triggered, and the Regulations attach legal consequences to the outcome of that inspection.

3. Expert insights

Insight one: the nonconforming product clauses demand a system, not merely a disposition outcome. §11.3 requires procedures covering the identification and documentation of nonconforming product, evaluation of the nonconformity to determine whether an investigation is needed, notification of the responsible parties, segregation and disposition of the nonconforming product, and documentation of the evaluation and any follow-up investigation. §11.4 goes further and requires defined responsibilities and authority, a documented review and disposition process, and documented justification and authorisation for any use of nonconforming product. §11.5–§11.6 require rework procedures to include retesting and re-evaluation after rework, with the results recorded in the Device History Record (DHR), together with the determination and documentation of any adverse effect of the rework on the product. In inspection practice, the difference between a passing and a failing answer often lies in whether these records exist for real batches.

Insight two: the five elements of the CAPA procedure are written concretely and can be used directly as an internal audit checklist. §11.7 requires the CAPA procedure to include: a) analysing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product and other sources of quality data to identify existing and potential causes of nonconforming product or other quality problems; b) employing appropriate statistical methods where necessary to detect recurring quality problems; c) investigating the cause of nonconformities relating to product, processes and the quality system; d) identifying the action needed to correct and prevent recurrence; and e) verifying or validating the corrective and preventive actions to confirm that they are effective and do not adversely affect the finished device. Companies should mirror the same five letters in their own CAPA procedure so the mapping is self-evident during inspection.

Insight three: there is a direct pathway from GMP findings to loss of the registration certificate. Regulation 8(1)(e) provides that where any premises used for the manufacture, assembly or storage of devices on behalf of the registration holder fail to meet officially determined GMP, good distribution practice (GDP) or good warehousing practice (GWP) requirements, the Agency may suspend or cancel the registration. In parallel, Regulation 4(10)(c) lists an unsatisfactory GMP inspection report as a ground for rejection of an application. The message is unambiguous: quality system problems surface directly in the licensing status of the product.

Insight four: labelling is treated as a controlled process, not a printed artefact. §12.1 requires quality assurance procedures to ensure that labelling conforms to the legibility and adhesion standards of the Device Master Record (DMR), and that labelling operations are controlled to ensure that the correct labels are always used. The scope of labelling includes device labels, control labels, packaging labels, instructions for use, maintenance manuals, and electronic displays that provide directions or warnings. §12.7 requires that packaging and labelling materials be inspected on receipt, and that label proofs be proofread by a designated individual, with the outcome recorded in the DHR. This process view extends labelling compliance from artwork design into receiving inspection, line clearance and record-keeping.

Insight five: complaint records must be retained for at least one year beyond expiry. §13.1(f) requires all relevant records to be maintained for at least 1 year beyond the expiry date of the device, or for 1 year from the date the complaint was received, whichever is longer. Complaint records should be reviewed periodically to identify and address recurring problems, and the regulatory authority must be informed promptly of any serious quality problem. §13.2 additionally requires periodic mock recalls to test the effectiveness of the recall procedure. Companies with long-shelf-life devices should note that the whichever-is-longer rule can push actual retention far beyond one year, so retention schedules should be calculated per product.

4. Practical recommendations

1. Run a clause-by-clause internal gap check against §11.3–§11.7 (nonconforming product, rework, and the five CAPA elements), and evidence every gap closure with real records.
2. Build the DHR into a searchable record system covering label proofreading and rework re-evaluation, so that inspection requests can be answered within minutes.
3. Establish labelling SOPs, master records and change traceability under §12.1–§12.7, including version, approval and rationale for every change.
4. Set complaint record retention to a floor of one year beyond expiry, calculated per product, and review complaint files on a defined periodic cycle.
5. Conduct at least one mock recall per year and retain the drill records, including reconciliation figures, as inspection evidence.

Taken together, these five actions convert the guideline from a compliance reference into an operating routine, so that an inspection becomes a demonstration exercise rather than a scramble to assemble documents.

5. Verification checklist

• □ DER-GDL-025-00 (effective 2024-11-11) has been obtained and communicated internally.
• □ The nonconforming product procedure covers identification, evaluation, notification, segregation, disposition and documentation.
• □ The rework procedure includes retesting and re-evaluation and records the results in the DHR.
• □ The CAPA procedure contains the five elements, including effectiveness verification.
• □ Labelling SOPs, master records and receipt inspection and proofreading records have been established under §12.
• □ Complaint record retention is ≥ 1 year beyond expiry; mock recalls are conducted on a defined periodic cycle.

Regulatory information verified as of 29 October 2026. All provisions cited above were checked against the GMP guideline (DER-GDL-025-00, effective 2024-11-11), the registration guideline (R&R-GDL-008-02 §5.0–§5.1) and the Regulations (S.I. No. 42 of 2024, Regulations 4(10)(c) and 8(1)(e)) as published on the NAFDAC website; this review is refreshed whenever the regulations are updated.

GRZAN supports manufacturers entering the Nigerian market with registration documentation and conformity files, including classification determination, registration pathway selection, technical documentation to the IMDRF ToC, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal. Local resources in Nigeria cover licensed import entities and authorised representative services, NAPAMS online submission, dossier screening permit liaison, import permits, sample delivery and laboratory analysis support. Contact: hito.lin@grzan.cn; website www.grzan.cn.